H. Lundbeck A — Earnings Release 2014

Aug 7, 2014

-- New Products on track and reached DKK 1,901 million in revenue driven by
Abilify Maintena®, Onfi®, Treanda® and the recent launch of Brintellix®
-- US revenue was DKK 1,626 million, an increase of 42% in local currency.
Onfi, Sabril® and Xenazine® continue their solid momentum, increasing 93%,
32% and 17% respectively in local currency and together with the launch
uptake from Brintellix and Abilify Maintena all contributing to the strong
growth in the US
-- Revenue from International Markets increased 10% in local currency, largely
driven by markets such as Canada and China
-- Brintellix demonstrated a good volume uptake and
has reached more than 120,000 prescriptions
since the US launch in January 2014
-- The market access for Abilify Maintena
in Europe is going well and the product has now been launched in Germany,
UK and the Nordic countries
-- Lundbeck has strengthened its very successful US neurology franchise by the
inclusion of Northera(TM) approved for neurogenic orthostatic hypotension
-- Significant new data strengthening the clinical profile on Brintellix. A
third study on cognition was presented at the International College of
Neuropsychopharmacology (CINP) World Congress, showing that Brintellix has
a statistically significant improvement in the cognitive performance
assessed by DSST versus placebo
-- The US regulatory approval process for brexpiprazole for the treatment of
schizophrenia, and as adjunctive therapy for the treatment of major
depression, has been initiated
-- The first of two phase III clinical studies (DIAS-3) in patients with acute
ischaemic stroke did not meet the primary endpoint. However, when analyzing
only the patients fulfilling protocol requirements desmoteplase showed an
effect relative to placebo
-- The financial guidance for 2014 is maintained

In connection with the interim report, Lundbeck’s President and CEO Ulf
Wiinberg said:

“The first half of 2014 has shown good progress for Lundbeck, from a strategic,
commercial and development point of view. We have reinforced our strategic
position as a global player within brain diseases with the recent acquisition
of Northera and the regulatory submission of brexpiprazole in the US. We are
encouraged by the early launch uptake from our new products and look forward to
the second half of 2014 where we will launch Northera in the US and Brintellix,
Abilify Maintena and Selincro in some of our major markets.”

DKK million H1 2014 H1 2013 Growth

Core Revenue 7,035 7,374 (5%)
Core EBIT 1,168 1,487 (21%)
Core EPS* 3.55 5.75 (38%)
Core EBIT margin 17% 20%
Reported Revenue 7,035 8,112 (13%)
Reported EBIT 843 1,020 (17%)
Reported EPS 2.42 2.88 (16%)
Reported EBIT margin 12% 13%